- Home
- TRIB vs MBRX Comparison
TRIB vs MBRX Comparison
Compare TRIB & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRIB
- MBRX
- Stock Information
- Founded
- TRIB 1992
- MBRX 2015
- Country
- TRIB Ireland
- MBRX United States
- Employees
- TRIB N/A
- MBRX N/A
- Industry
- TRIB Biotechnology: In Vitro & In Vivo Diagnostic Substances
- MBRX Biotechnology: Pharmaceutical Preparations
- Sector
- TRIB Health Care
- MBRX Health Care
- Exchange
- TRIB Nasdaq
- MBRX Nasdaq
- Market Cap
- TRIB 13.0M
- MBRX 12.9M
- IPO Year
- TRIB N/A
- MBRX 2016
- Fundamental
- Price
- TRIB $0.75
- MBRX $0.34
- Analyst Decision
- TRIB
- MBRX Strong Buy
- Analyst Count
- TRIB 0
- MBRX 3
- Target Price
- TRIB N/A
- MBRX $5.33
- AVG Volume (30 Days)
- TRIB 2.4M
- MBRX 5.1M
- Earning Date
- TRIB 08-13-2025
- MBRX 08-13-2025
- Dividend Yield
- TRIB N/A
- MBRX N/A
- EPS Growth
- TRIB N/A
- MBRX N/A
- EPS
- TRIB N/A
- MBRX N/A
- Revenue
- TRIB $61,555,000.00
- MBRX N/A
- Revenue This Year
- TRIB $13.51
- MBRX N/A
- Revenue Next Year
- TRIB $13.14
- MBRX N/A
- P/E Ratio
- TRIB N/A
- MBRX N/A
- Revenue Growth
- TRIB 8.31
- MBRX N/A
- 52 Week Low
- TRIB $0.48
- MBRX $0.25
- 52 Week High
- TRIB $3.44
- MBRX $4.71
- Technical
- Relative Strength Index (RSI)
- TRIB 58.59
- MBRX 30.62
- Support Level
- TRIB $0.63
- MBRX $0.29
- Resistance Level
- TRIB $0.77
- MBRX $0.36
- Average True Range (ATR)
- TRIB 0.08
- MBRX 0.05
- MACD
- TRIB 0.01
- MBRX 0.00
- Stochastic Oscillator
- TRIB 63.64
- MBRX 21.55
About TRIB Trinity Biotech plc
Trinity Biotech PLC is in the business of developing, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point-of-care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Immublot, and others. Geographically, it has two segments namely the Americas, and the Rest of World - Ireland from which it derives a majority of its revenue from the Americas segment.
About MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.